

*Amendments to the Claims*

The listing of claims will replace all prior versions, and listing of claims in the application.

1. (Currently Amended) A pharmaceutical composition which comprises a sodium channel blocker in combination with a selective serotonin uptake inhibitor, wherein said pharmaceutical composition when administered to a mammal has improved therapeutical indices compared to the administration of a pharmaceutical composition comprising only a sodium channel blocker.

2. (Original) A pharmaceutical composition according to claim 1, wherein the selective serotonin uptake inhibitor is selected from the group consisting of fluoxetine, paroxetine, duloxetine, sertraline, escitalopram and citalopram.

3. (Currently Amended) A pharmaceutical composition according to claim 1, wherein the sodium channel blocker is selected from the group consisting of lamotrigine, crobenetine, oxcarbamazepine and phosphenytoin ~~phosphenytoin~~.

4. (Currently Amended) A pharmaceutical composition according to ~~any of claims 1, 2 or 3~~ claim 1, wherein the selective serotonin uptake inhibitor is fluoxetine and the sodium channel blocker is lamotrigine.

5. (Withdrawn – Currently Amended) A pharmaceutical composition according to ~~any of claims 1, 2 or 3~~ claim 1, wherein the selective serotonin uptake inhibitor is fluoxetine and the sodium channel blocker is crobenetine.

6. (Currently Amended) A pharmaceutical composition according to ~~any of claims 1, 2 or 3~~ claim 1, wherein the selective serotonin uptake inhibitor is sertraline and the sodium channel blocker is lamotrigine.

7. (Withdrawn – Currently Amended) A pharmaceutical composition according to ~~any of claims 1, 2 or 3~~ claim 1, wherein the selective serotonin uptake inhibitor is sertraline and the sodium channel blocker is crobenetine.

8-15. (Canceled).

16. (Currently Amended) A method for the treatment of a disease occurring in a mammal, said disease involving chronic pain, epilepsy or deriving from disorders and/or injuries of the motor system, ~~characterized in that~~ comprising administering to a mammal in need of such treatment a therapeutically effective amount of pharmaceutical composition comprising a sodium channel blocker and a selective serotonin uptake inhibitor ~~is given to the subject in need of such treatment~~ wherein said pharmaceutical composition when administered to a mammal has improved therapeutical indices compared to the administration of a pharmaceutical composition comprising only a sodium channel blocker.

17. (Canceled).

18. (Currently Amended) A method according to claim 16 ~~or 24~~, wherein the selective serotonin uptake inhibitor is selected from the group consisting of fluoxetine, paroxetine, duloxetine, sertraline, escitalopram and citalopram.

19. (Currently Amended) A method according to claim 16 ~~or 24~~, wherein the sodium channel blocker is selected from the group consisting of lamotrigine, crobenetine, oxcarbamazepine and phosphenytoin ~~phosphenytoin~~.

20. (Currently Amended) A method according to claim 16 ~~or 24~~, wherein the selective serotonin uptake inhibitor is fluoxetine and the sodium channel blocker is lamotrigine.

21. (Withdrawn – Currently Amended) A method according to claim 16 ~~or~~ 17, wherein the selective serotonin uptake inhibitor is fluoxetine and the sodium channel blocker is crobenetine.

22. (Currently Amended) A method according to claim 16 ~~or~~ 24, wherein the selective serotonin uptake inhibitor is sertraline and the sodium channel blocker is lamotrigine.

23. (Withdrawn – Currently Amended) A method according to claim 16 ~~or~~ 17, wherein the selective serotonin uptake inhibitor is sertraline and the sodium channel blocker is crobenetine.

24. (Canceled).